Peer Review History
| Original SubmissionJune 18, 2021 |
|---|
|
PReventing Idiopathic SCOliosis PROgression (PRISCOPRO) : a protocol for a quadruple-blinded, randomized controlled trial comparing 3D designed Boston brace to standard Boston brace PONE-D-21-16829 Dear Dr. Diarbakerli, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Nancy Beam, PhD Staff Editor PLOS ONE Journal requirements: 1. Thank you for stating the following financial disclosure: [The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.].
Please send your amended statements by return email; we will change the online submission form on your behalf. 2. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed: - https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-14-261 - https://clinicaltrials.gov/ct2/show/NCT04805437 In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed. |
| Formally Accepted |
|
PONE-D-21-16829 PReventing Idiopathic SCOliosis PROgression (PRISCOPRO): a protocol for a quadruple-blinded, randomized controlled trial comparing 3D designed Boston brace to standard Boston brace Dear Dr. Diarbakerli: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Nancy Beam Staff Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .